GLA anticorps (AA 80-429)
Aperçu rapide pour GLA anticorps (AA 80-429) (ABIN7114449)
Antigène
Voir toutes GLA AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- AA 80-429
-
Fonction
- GLA antibody
-
Purification
- Protein A+G purification
-
Pureté
- ≥95 % as determined by SDS-PAGE
-
Immunogène
-
Immunogen sequence: 80-429aa
Immunogen: galactosidase, alpha
-
Isotype
- IgG2a
-
-
-
-
Indications d'application
- WB: 1:500-1:2000, IHC: 1:20-1:200, IF: 1:20-1:200
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Avoid repeated freeze / thaw cycles.
-
Stock
- -20 °C
-
Stockage commentaire
- -20°C for 12 months
-
Date de péremption
- 12 months
-
-
- GLA (Galactosidase, alpha (GLA))
-
Autre désignation
- GLA
-
Sujet
-
Synonyms: Alpha-galactosidase A|Alpha-D-galactosidase A|Alpha-D-galactoside galactohydrolase|Galactosylgalactosylglucosylceramidase GLA|Melibiase|GLA
Background: GLA, also named as Melibiase, Agalsidase and Alpha-galactosidase A, belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.
-
Poids moléculaire
- 49 kDa
-
ID gène
- 2717
-
UniProt
- P06280
-
Pathways
- SARS-CoV-2 Protein Interactome
Antigène
-